Twenty-nine patients with multiple myeloma, 16 untreated and 13 relapsing after treatment with melphalan and/or cyclophosphamide, were treated with Peptichemio (PTC), vincristine (VCR) and prednisone (PRD). The treatment was well tolerated and produced rapid resolution of bone pain and improved performance status in symptomatic patients. Rapid and marked monoclonal component reduction (> 50 per cent) was noted in 50 % of previously untreated and 31 % of previously treated patients. The median survival of previously untreated patients was 27 months, 19 months for stage III patients. Four patients resistant to common alkylating agents responded to PTC-VCR-PRD treatment and achieved long remissions (from 18 to 38 months). The therapeutic results suggest that the present combination regimen may be indicated for induction treatment of multiple myeloma patients in an advanced stage of the disease, and for treatment of myeloma patients refractory or resistant to melphalan and/or cyclophosphamide.
Get full access to this article
View all access options for this article.
References
1.
AlbertsD.S., DurieB.G.M., SalmonS.E.: Treatment of multiple myeloma in remission with anticancer drugs having cell cycle specific characteristics.Cancer Treat. Rep., 61: 381–388, 1977.
AlexanianR., DreicerR.: Chemotherapy for multiple myeloma.Cancer, 53: 583–588, 1984.
6.
BergsagelD.: Progress in the treatment of plasma cell myeloma? J.Clin. Oncol., 1: 510–512, 1983.
7.
CaseD.C., LeeB.J., ClarksonB.D.: Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol.Am. J. Med., 63: 897–903, 1977.
8.
CavoM., GobbiM., TuraS.: Peptichemio in multiple myeloma.Haematologica, 66: 208–215, 1981.
9.
Chronic Leukemia Myeloma Task Force: Proposed guidelines for protocol studies. II. Plasma cell myeloma.Cancer Chemother. Rep., 3: 1–17, 1968.
10.
CostaG., EngleR.L.Jr., SchillingA., CarboneP., KochwaS., NachmanR.L., GlidewellO.: Melphalan and prednisone: An effective combination for the treatment of multiple myeloma.Am. J. Med., 54: 589–599, 1973.
11.
CuttnerJ., WassermanL.R., MartzG., SonntagR.W., KyleR.A., SilverR.T., SpurrC., HarleyJ.B., WiernikP.M., CornwellG.G.III, FalksonG., GlidewellO., HollandJ.F.: The use of low-dose prednisone and melphalan in the treatment of poor-risk patients with multiple myeloma.Med. Ped. Oncol., 1: 207–216, 1975.
12.
De BarbieriA., ChiappinoG., Di VittorioP., GolferiniA., MaugeriM., MistrettaA.P., PerroneF., TassiG.C., TemelcouO., ZapelliP.: Peptichemio. A synthesis of pharmacological, morphological, biochemical and biomolecular investigations. In: Proceedings Symposium on Peptichemio.De BarbieriA. (ed.), pp. 4–46, I.S.M., Milan, 1972.
13.
DurieB.G.M., SalmonS.E.: The current status and future prospects of treatment for multiple myeloma.Clin. Haematol., 11: 181–210, 1982.
14.
E.O.R.T.C: A phase II clinical trial of Peptichemio.Biomedicine, 27: 290–294, 1977.
15.
GingoldN., PittermannE., StacherA.: Peptichemio in the therapy of malignancies (phase-I-study).Int. J. Clin. Pharmacol., 10: 190–202, 1974.
16.
HarleyJ.B., PajakT.F., McIntyreO.R., KochwaS., CooperM.R., ColemanM., CuttnerJ.: Improved survival of increased-risk myeloma patients on combined triple-alkylating-agent therapy: A study of the CALGB.Blood, 54: 13–22, 1979.
17.
McLaughlinP., AlexanianR.: Myeloma protein kinetics following chemotherapy.Blood, 60: 851–855, 1982.
18.
MerliniG.P., WaldenströmJ.C., JayakarS.: A new improved clinical staging system for multiple myeloma based on analysis of 123 treated patients.Blood, 55: 1011–1019, 1980.
PavloskyS., SaslavskyJ., Tezanos PintoM., PalmerL., CuruchetM., LeinJ.M., GarayG., DragoskyM., Quiroga-MicheoE., HubermanA.B., PizzolattoM.: A randomized trial of melphalan and prednisone versus melphalan, prednisone, cyclophosphamide, MeCCNU and vincristine in untreated multiple myeloma.J. Clin. Oncol., 2: 836–840, 1984.
21.
PeruginiS., Bobbio PallaviciniE., GhizziA., RiccardiA., MartinottiA., MerliniG.: Peptichemio in the treatment of plasma cell leukemia.Haematologica, 61: 248–249, 1976.
22.
RiccardiA., MerliniG.P., MontecuccoC.M., PeruginiS.: Vincristine in the treatment of multiple myeloma.Haematologica, 65: 595–611, 1980.
23.
RiccardiA., MontecuccoC.M., MerliniG., UcciG., CremoniniM., AscariE.: Proliferative activity, response to therapy and survival in multiple myeloma.Haematologica, 69: 148–162, 1984.
24.
SalmonS.E., HautA., BonnetJ.D., AmareM., WeickJ.K., DurieB.G.M., DixonD.O.: Alternating combination chemotherapy and levamisole improves survival in multiple myeloma. A Southwest Oncology Group study.J. Clin. Oncol., 1: 453–461, 1983.
25.
WochnerR.D., StraberW., WaldmanT.A.: The role of the kidney in the catabolism of Bence Jones proteins and immunoglobulin fragments J.Exp. Med., 126: 207–221, 1967.
